A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

  • Tai, Anna (Investigator 01)

Project Details

StatusFinished
Effective start/end date5/07/21 → 7/07/23

Funding

  • AbbVie Pty Ltd: A$67,282.00